Document is current
Any future updates will be listed below
-
Authors
Fan, Yizeng https://orcid.org/0000-0001-7710-5458
Wang, Yuzhao https://orcid.org/0000-0003-4697-409X
Dan, Weichao
Zhang, Yilei https://orcid.org/0000-0003-1407-0301
Nie, Li https://orcid.org/0000-0002-6976-0425
Ma, Zhiqiang
Zhuang, Yanxin
Liu, Bo
Li, Mengxing
Liu, Tianjie https://orcid.org/0000-0002-2321-1869
Wang, Zixi
Ye, Leihong
Wei, Yi
Lei, Yuzeshi https://orcid.org/0000-0001-7769-8409
Guo, Chendong
An, Jiale
Wang, Chi
Zhang, Yulin
Zeng, Jin
Wei, Wenyi https://orcid.org/0000-0003-0512-3811
Gan, Boyi https://orcid.org/0000-0001-8884-6040
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (81925028, 82230097)
National Key Research and Development Program of Chin
- License Information
-
More Information
Article History
Received: 3 May 2024
Accepted: 3 January 2025
First Online: 3 March 2025
Competing interests
: W.W. is a co-founder and consultant for Rekindle Therapeutics. B.G. reports receiving consultation fees from Guidepoint Global, Cambridge Solution and NGM Bio, and is an inventor with patent applications involving targeting ferroptosis in cancer therapy. The other authors declare no competing interests.
